Skip to content

A Study to See if an Energy Drink With Caffeine and Green Tea Increases Fat Burning When Exercising

Influence of Caffeine and Green Tea Extracts Consumption on Basal, Peri- and Post-exercise Fat Oxidation

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07434752
Enrollment
36
Registered
2026-02-27
Start date
2026-03-26
Completion date
2026-09-18
Last updated
2026-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exercise

Keywords

metabolism

Brief summary

The goal of this study is to evaluate the influence of consuming a drink containing a combination of caffeine and green tea extracts on fat oxidation responses at rest, during and after a period of endurance type exercise.

Detailed description

This study investigates whether consuming an energy drink containing caffeine and green tea extract before exercise increases fat burning (oxidation) compared with a placebo drink. Healthy, moderately active adults will attend three visits at clinic over 3-5 weeks. The first visit determines each participant's individual exercise intensity that maximises fat use during cycling. At two subsequent visits, participants will consume either the active drink or a placebo before completing a 30-minute cycling session at their personalised intensity. Fat and carbohydrate use, heart rate, blood pressure, and subjective responses will be measured at rest, during exercise, and after exercise using a double-blind, crossover design.

Interventions

DIETARY_SUPPLEMENTActive (Green tea and caffeine)

Two 355 mL cans of "XS Energy + BURN" drink containing caffeine and green tea extract.

OTHERPlacebo

Two 355 mL cans of placebo drink but without the active ingredients (caffeine and green tea extract).

Sponsors

RDC Clinical Pty Ltd
Lead SponsorINDUSTRY
Amway Corp
CollaboratorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Passing the Exercise and Sport Science Australia adult pre-exercise screening system (APSS) stage 1 \& 2 (see appendix 4). * Between the ages of 18 and 45, * Not sedentary, and not completing more than 150 minutes of low and/or moderate and/or or vigorous intensity endurance exercise a week, * Ability to commit to in principle fulfilment of all 3 trial visits, * No history of coagulopathy e.g., DVT, stroke, * No known heart disease, * No known pancreatic insufficiency, * No known inflammatory bowel disease, or prior bowel resection or bypass surgery (excluding gastric banding and sleeve), * BMI of 22.0 to 34.9 kg/m2, * No known allergies to caffeine or green tea extract, * No known type I or II diabetes, * No uncontrolled concurrent illness, * No known current pregnancy or breastfeeding women * No current regular consumption of supplements (\>2 times a week) or foods and drinks containing caffeine and/or green tea extracts (\>2 times per day, weekly). * Agree not to consume caffeine for 12-hours prior to the clinic visit.

Exclusion criteria

* Triggering any of the exclusion screening criteria as outlined below, and in compliment with the Exercise and Sport Science Australia adult pre-exercise screening system (APSS). * Under the age of 18 or over the age of 45, * Sedentary, or completing over 150 minutes of low and/or moderate and/or or vigorous intensity endurance exercise a week, * Inability to commit to in principle fulfilment of all 3 trial visits, * History of coagulopathy e.g., DVT, stroke, * Known heart disease, * Known pancreatic insufficiency, * Known inflammatory bowel disease, or prior bowel resection or bypass surgery (excluding gastric banding and sleeve), * BMI \< 22.0 or \> 34.9 kg/m2, * Known allergies to caffeine or green tea extract, * Known type I or II diabetes, * Uncontrolled concurrent illness, * Taking GLP-1 agonists, caffeine, or any other medication known to affect metabolism. * Known current pregnancy or breastfeeding women. * Currently regularly consuming supplements, foods or drinks containing a caffeine and green tea extract blend, or not willing to abstain for the study

Design outcomes

Primary

MeasureTime frameDescription
Fat oxidation as measured by indirect calorimetryBaseline to 30 mins post exerciseChange from baseline to the end of the study period in Fat oxidation as measured by indirect calorimetry (metabolic cart); baseline (pre-drink), post-drink (pre-exercise), time sequence e.g., every 5-min during exercise, 10, 20 and 30-min post-exercise. Change from baseline \& total. Fat oxidation will be measured continuously throughout the exercise and the 30-min post-exercise window, to facilitate total, and any other temporal fat oxidation timepoints.

Secondary

MeasureTime frameDescription
Carbohydrate oxidation; indirect calorimetryBaseline to 30 mins post exerciseChange from baseline to the end of the study period in Carbohydrate oxidation; indirect calorimetry; same timing as fat oxidation (baseline (pre-drink), post-drink (pre-exercise), time sequence e.g., every 5-min during exercise, 10, 20 and 30-min post-exercise.). Change from baseline \& total.
Respiratory exchange ratio; indirect calorimetryBaseline to 30 mins post exerciseChange from baseline to the end of the study period in Respiratory exchange ratio; indirect calorimetry; same timing as fat oxidation (baseline (pre-drink), post-drink (pre-exercise), time sequence e.g., every 5-min during exercise, 10, 20 and 30-min post-exercise). Change from baseline \& total
Exercise efficiency; indirect calorimetryBaseline to 30 mins post exerciseChange from baseline to the end of the study period in Exercise efficiency; indirect calorimetry; time sequence during exercise e.g., every 5-min. Change from the beginning of exercise \& average

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 10, 2026